INTERIM RESULTS FROM A SINGLE-ARM MULTICENTER PHASE II TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)

被引：2
|
作者：
Packiam, Vignesh T.
Barocas, Daniel A.
Chamie, Karim
Davis, Ronald L., III
Kader, A. Karim
Lamm, Donald L.
Curran, Dominic
Yeung, Alex W.
Steinberg, Gary D.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 04期
关键词：
D O I：
10.1016/j.juro.2017.03.039
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PNFLBA-13
引用
收藏
页码：E915 / E916
页数：2
相关论文
共 50 条
  • [31] Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label study
    Hurle, Rodolfo
    Casale, Paolo
    Morenghi, Emanuela
    Saita, Alberto
    Buffi, Nicolomaria
    Lughezzani, Giovanni
    Colombo, Piergiuseppe
    Contieri, Roberto
    Frego, Nicola
    Guazzoni, Giorgio
    Lazzeri, Massimo
    BJUI COMPASS, 2020, 1 (04): : 126 - 132
  • [32] PHASE 3 STUDY OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: INITIAL RESULTS
    Dickstein, Rian
    Wu, Ning
    Cowan, Barrett
    Dunshee, Curtis
    Franks, Michael
    Wolk, Fred
    Belkoff, Laurence
    Castelucci, Sean
    Holzbeierlein, Jeffrey
    Kulkarni, Girish
    Weizer, Alon
    Lamm, Donald
    Brooks, David
    Epstein, Jonathon
    Ali, Syed
    Kassouf, Wassim
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1167 - E1167
  • [33] FINAL RESULTS OF A PHASE I, SINGLE-ARM CLINICAL TRIAL OF THE COMBINATION OF DURVALUMAB AND VICINEUM IN BCG UNRESPONSIVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS (NCT03258593)
    Rivera-Marquez, Genesis
    Walter, Beatriz
    Dolan, Rebecca
    Belfield, Sonia
    Merino, Maria
    Gurram, Sandeep
    Apolo, Andrea
    Niglio, Scot
    Agarwal, Piyush
    Valera, Vladimir A.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E248 - E248
  • [34] AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS)
    Kulkarni, Girish
    Richards, Kyle
    Black, Peter C.
    Rendon, Ricardo
    Chin, Joseph
    Shore, Neal
    Jayram, Gautam
    Kramolowsky, Eugene
    Saltzstein, Daniel
    Agarwal, Piyush
    Belkoff, Laurence
    O'Donnell, Michael
    Kamat, Ashish M.
    Zlotta, Alexandre
    Jewett, Michael A. S.
    Lamm, Donald
    DeGruttola, Victor
    Mandel, Arkady
    Dumoulin-White, Roger J.
    Kassouf, Wassim
    JOURNAL OF UROLOGY, 2023, 209 : E871 - E871
  • [35] Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).
    Li, Roger
    Spiess, Philippe E.
    Sexton, Wade J.
    Gilbert, Scott Michael
    Poch, Michael Adam
    Pow-Sang, Julio M.
    Zhang, Jingsong
    Dhillon, Jasreman
    Thomas, Kerry
    Borjas, Gustavo
    Bala, Juliet
    Grandi, Paola
    Burke, James
    Mule, James J.
    Conejo-Garcia, Jose
    Jain, Rohit K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] EVALUATING INTRAVESICAL NADOFARAGENE FIRADENOVEC AND IMMUNE CHECKPOINT BLOCKADE COMBINATION THERAPY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM A PHASE 3 TRIAL
    Mitra, Anirban P.
    Mokkapati, Sharada
    Miest, Tanner S.
    Narayan, Vikram M.
    Philipson, Richard
    Yla-Herttuala, Seppo
    Sawutz, David
    Parker, Nigel R.
    McConkey, David J.
    Dinney, Colin P. N.
    JOURNAL OF UROLOGY, 2022, 207 (05): : E927 - E928
  • [37] Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).
    Black, Peter C.
    Tangen, Catherine
    Singh, Parminder
    McConkey, David James
    Lucia, Scott
    Lowrance, William Thomas
    Koshkin, Vadim S.
    Stratton, Kelly Lynn
    Bivalacqua, Trinity
    Kassouf, Wassim
    Porten, Sima P.
    Bangs, Rick
    Plets, Melissa
    Lerner, Seth P.
    Thompson, Ian Murchie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).
    Black, Peter C.
    Catherine, Tangen
    Lerner, Seth P.
    McConkey, David James
    Lucia, M. Scott
    Woods, Michael
    Bivalacqua, Trinity
    Kassouf, Wassim
    Bangs, Richard Carlton
    Plets, Melissa
    Thompson, Ian Murchie
    Singh, Parminder
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Activity of intravesical CG0070 in Rb-inactive superficial bladder cancer after BCG failure: Updated results of a phase I/II trial
    Friedlander, Terence W.
    Weinberg, Vivian K.
    Yeung, Alex
    Burke, James
    Lamm, Donald L.
    McKiernan, James M.
    Nemunaitis, John J.
    Stephenson, Joe
    Small, Eric Jay
    Fong, Lawrence
    Meng, Maxwell V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] ELICITATION OF HEALTH STATE UTILITIES ASSOCIATED PROGRESSION FROM BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) HEALTH STATES
    Cooper, O.
    Rentz, A.
    Piglowska, N.
    Smith, C.
    Jakobsen, J.
    Catto, J.
    Niegisch, G.
    Ghatnekar, O.
    Swinburn, P.
    VALUE IN HEALTH, 2022, 25 (07) : S288 - S288
12345